The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
Young, Jim (University Hospital Basel (Basilea, Suïssa))
Weis, Nina (Copenhagen University Hospital)
Hofer, Harald (Medical University of Vienna)
Irving, William (University of Nottingham)
Weiland, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia))
Giostra, Emiliano (Hôpitaux universitaires de Genève)
Pascasio, Juan Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Castells, Lluís (Hospital Universitari Vall d'Hebron)
Prieto, Martin (Hospital Universitari i Politècnic La Fe (València))
Postema, Roelien (Bristol-Myers Squibb)
Lefevre, Cinira (Bristol-Myers Squibb)
Evans, David (Bristol-Myers Squibb)
Bucher, Heiner (University Hospital Basel (Basilea, Suïssa))
Calleja, Jose Luis (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Universitat Autònoma de Barcelona

Data:	2017
Resum:	There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options. A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of sustained virologic response for patients receiving daclatasvir and sofosbuvir with or without ribavirin using hierarchical Bayesian modelling. The 249 patients included had a median age of 56 years; most were male (78%), hepatitis C genotype 1 (75%), treatment experienced (65%) and with decompensated cirrhosis (59%). Many had had a liver transplant before receiving daclatasvir (40%). Of the 249 patients, 242 patients received daclatasvir and sofosbuvir and either reached 12 weeks post treatment or died during (n = 9) or after treatment (n = 4) or were lost to follow up during treatment (n = 1). The estimated rate of sustained virologic response at 12 weeks post treatment was 87% (95% credible interval 75 to 94%) for previously treated genotype 1 patients with decompensated cirrhosis. Daclatasvir with sofosbuvir is an effective treatment in clinical practice for hepatitis C genotype 1 patients with decompensated cirrhosis. The online version of this article (doi:10. 1186/s12879-016-2106-x) contains supplementary material, which is available to authorized users.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Daclatasvir ; Direct-acting antivirals ; Effectiveness ; Hepatitis C ; Sofosbuvir
Publicat a:	BMC Infectious diseases, Vol. 17 (january 2017) , ISSN 1471-2334

DOI: 10.1186/s12879-016-2106-x
PMID: 28061762

8 p, 722.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats